^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ProTmune (FT1050+FT4145 programmed mPB)
i
Other names: FT1050+FT4145 programmed mPB, FT1050+FT4145 programmed mobilized peripheral blood (mPB)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Fate Therap
Drug class:
Immunomodulator
Related drugs:
over2years
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=89, Completed, Fate Therapeutics | Active, not recruiting --> Completed
Trial completion • Preclinical
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
ProTmune (FT1050+FT4145 programmed mPB)
over3years
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=80, Active, not recruiting, Fate Therapeutics | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Mar 2020 --> Dec 2020
Clinical • Preclinical • Trial completion date • Trial primary completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
ProTmune (FT1050+FT4145 programmed mPB)
4years
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=80, Active, not recruiting, Fate Therapeutics | Recruiting --> Active, not recruiting
Clinical • Enrollment closed • Preclinical
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
ProTmune (FT1050+FT4145 programmed mPB)
Share via
